-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 30th, AbbVie announced that the U.
S.
FDA has approved the listing of Vuity (pilocarpine 1.
25% ophthalmic solution) from its subsidiary Allergan Company for the treatment of presbyopia
.
The press release states that this is the first eye drop therapy approved by the FDA for the treatment of presbyopia
Presbyopia affects nearly 2 billion people worldwide, and there are currently no effective drug solutions available for patients
.
Now, patients can only choose to wear reading glasses, which is inconvenient for many patients
Vuity is an innovative and optimized ophthalmic formula of pilocarpine
.
Its main mechanism of action is to constrict the pupils, thereby enhancing the depth of field and improving near vision and intermediate vision
This approval is supported by data from two pivotal Phase 3 clinical trials involving approximately 750 patients.
The data showed that on the 30th day of treatment, compared with placebo, patients treated with Vuity were able to obtain indicators of near vision testing.
Significantly improved, at the same time this eye drops will not affect the patient's distance vision
.
It takes effect as soon as 15 minutes after instillation, and the effect can last for 6 hours
In terms of safety, no serious adverse reactions related to treatment were found.
Note: The original text has been deleted
Reference materials:
[1] NDA APPROVAL.
[3] US Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.
